Prenetics utilizes DNA sequencing technology to provide genetic and diagnostic health testing, enabling individuals to identify specific health risks. The company also focuses on early cancer detection through its Insighta venture, which employs advanced genomic profiling to improve screening outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for early cancer detection often lack the sensitivity and specificity needed to identify tumors at their earliest stages, leading to delayed diagnoses and reduced treatment options. Traditional screening approaches may also be invasive, costly, and inconvenient, limiting their widespread adoption and effectiveness.
Solution
Prenetics is developing advanced genomic profiling technologies through its Insighta venture to improve multi-cancer early detection. By leveraging next-generation sequencing (NGS) and AI-driven analytics, Insighta aims to identify cancer biomarkers in blood samples, enabling earlier and more accurate diagnoses. Prenetics' acquisition of ACT Genomics further enhances its capabilities in comprehensive genomic profiling of solid tumors, providing clinicians with actionable insights for personalized cancer treatment. CircleDNA, another Prenetics initiative, offers comprehensive DNA tests using NGS to identify individual health risks and predispositions, empowering individuals to take proactive steps towards prevention.
Target Audience
The primary target audience includes individuals seeking proactive health management through genetic testing, as well as healthcare providers looking for advanced diagnostic tools for early cancer detection and personalized treatment strategies.
Features
- Insighta: Multi-cancer early detection using advanced genomic profiling and AI-driven analysis.
- ACT Genomics: FDA-cleared comprehensive genomic profiling of solid tumors for personalized cancer treatment.
- CircleDNA: Comprehensive DNA testing using NGS to identify individual health risks and predispositions.
- Non-invasive blood tests for early cancer detection.
- Personalized risk assessment and preventative strategies based on genomic data.